恒瑞医药：SHR-1905注射液获得药物临床试验批准

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for clinical trials of SHR-1905 injection, a monoclonal antibody targeting TSLP, aimed at improving inflammatory conditions and controlling disease progression [1] Group 1: Product Development - SHR-1905 injection is designed to block the release of inflammatory cytokines and inhibit downstream inflammatory signaling [1] - The company has invested approximately 20.962 million yuan in the research and development of SHR-1905 injection to date [1] Group 2: Market Context - Tezepelumab, a similar product developed by AstraZeneca/Amgen, has been approved and is projected to generate global sales of approximately 1.22 billion USD in 2024 [1]